Passage Bio to Participate in Upcoming April Investor Conferences

Rhea-AI Summary

Passage Bio, a genetic medicines company focused on therapies for rare CNS disorders, announces participation in three virtual investor conferences. The events are scheduled for April 1, 13, and 26, 2021. The company aims to showcase its advancements in gene therapies and engage with investors. Webcasts of the events will be available on the company’s website, with replays for 30 days. Passage Bio collaborates with the University of Pennsylvania’s Gene Therapy Program to expedite its pipeline development. For more information, visit passagebio.com.

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming virtual investor conferences in April:

Guggenheim Healthcare Talks | 2021 Genomic Medicines & Rare Disease
Format: Panel
Date: Thursday, April 1, 2021
Time: 12:00 p.m. ET

Needham Healthcare Conference
Format: Presentation
Date: Tuesday, April 13, 2021
Time: 08:45 a.m. ET

Chardan 4^th Annual Manufacturing Summit
Format: Fireside chat
Date: Monday, April 26, 2021
Time: 11:15 a.m. ET

A live webcast of the events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation and fireside chat will be available for 30 days following the events.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com

FAQ

What investor conferences will Passage Bio participate in April 2021?

Passage Bio will participate in three virtual investor conferences: Guggenheim Healthcare Talks on April 1, Needham Healthcare Conference on April 13, and Chardan Annual Manufacturing Summit on April 26, 2021.

What is the date and time of the Guggenheim Healthcare Talks?

The Guggenheim Healthcare Talks will take place on April 1, 2021, at 12:00 p.m. ET.

How can I access the webcasts of Passage Bio's conferences?

Webcasts of Passage Bio's conferences will be available on their Investors & Media section on the company’s website.

What is the focus of Passage Bio's therapies?

Passage Bio focuses on developing transformative gene therapies for rare, monogenic central nervous system disorders.

Where is Passage Bio based?

Passage Bio is based in Philadelphia, PA.